Cellectis SA (CLLS) revenue breakdown
By product, Therapeutics is the largest at 53% of fiscal 2021 revenue; Plants grew fastest, 170% a year over 4 years.
By region, France is the largest at 53% of fiscal 2021 revenue; United States grew fastest, 132% a year over 5 years.
Revenue by product
Fiscal years, as Cellectis SA reports them in its 10-K filings; fiscal 2021 total $57M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|
| Therapeutics | $25M | $12M | $8M | $51M | $30M | 53% |
| Plants | $508,000 | $236,000 | $7M | $23M | $27M | 47% |
Revenue by region
Fiscal years, as Cellectis SA reports them in its 10-K filings; fiscal 2021 total $57M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|---|
| France | $44M | $25M | $12M | $8M | $51M | $30M | 53% |
| United States | $399,000 | $508,000 | $236,000 | $7M | $23M | $27M | 47% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLLS.
Open CLLS in InvestinglyQuestions
Where does Cellectis SA make its money?
In fiscal 2021, by product: Therapeutics $30M, Plants $27M.
From Cellectis SA's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.